Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn’s Disease

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Pediatric Crohn’s disease (CD) is characterized by an aggressive course that commonly requires more intensive pharmacological and surgical treatments. In spite of the therapeutic advances in monitoring and management, including the widespread use of biologic therapy, the cumulative incidence of surgery in children with CD is still high. However, surgery is usually not curative and disease recurrence after small bowel resection is common. Gastrointestinal endoscopy is currently the gold standard to evaluate disease progression after surgery, but other non-invasive methods have been suggested. Although the efficacy of several drugs as medical prophylaxis to reduce the rate of disease recurrence following intestinal resection has been evaluated, selecting the most appropriate preventive therapeutic intervention remains a challenge. The current recommendations, mostly based on adult studies due to limited pediatric data, state that treatment should be guided by risk for recurrence. Low-risk patients may be given no prophylaxis or only 5-ASA. Maintenance enteral nutrition may also be considered. Thiopurines may be used in moderate risk of CD recurrence. In high risk patients for postoperative recurrence (extensive disease, short disease duration from diagnosis to surgery, recurrent surgery, long resected segment, surgery for fistulizing disease, disease complications, perianal disease, smoking), prophylactic treatment with anti-TNFα is recommended. subsequently, therapy should be guided by repeated measurement of objective measures including endoscopic re-evaluation at 6–12 months following surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2012;46:581–9.

    PubMed  PubMed Central  Google Scholar 

  2. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–13.

    PubMed  Google Scholar 

  3. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006;130:1069–77.

    PubMed  Google Scholar 

  4. Kulungowski AM, Acker SN, Hoffenberg EJ, et al. Initial operative treatment of isolated ileal Crohn’s disease in adolescents. Am J Surg. 2015;210:141–5.

    PubMed  Google Scholar 

  5. Niewiadomski O, Studd C, Hair C, et al. Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity. J Gastroenterol Hepatol. 2015;30:1346–53.

    CAS  PubMed  Google Scholar 

  6. Rinawi F, Assa A, Hartman C, et al. Incidence of bowel surgery and associated risk factors in pediatric-onset Crohn’s disease. Inflamm Bowel Dis. 2016;22:2917–23.

    PubMed  Google Scholar 

  7. Stokes AL, Kulaylat AN, Rocourt DV, et al. Rates and trends for inpatient surgeries in pediatric Crohn’s disease in the United States from 2003 to 2012. J Pediatr Surg. 2018;53:1334–8.

    PubMed  Google Scholar 

  8. Hansen LF, Jakobsen C, Paerregaard A, et al. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60:347–51.

    PubMed  Google Scholar 

  9. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231:38–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–97.

    PubMed  Google Scholar 

  11. Kim HJ, Oh SH, Kim DY, et al. Clinical characteristics and long-term outcomes of paediatric Crohn’s disease: a single-centre experience. J Crohn’s Colitis. 2017;11:157–64.

    Google Scholar 

  12. Ashton JJ, Borca F, Mossotto E, et al. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther. 2019;49:398–407.

    CAS  PubMed  Google Scholar 

  13. Burr NE, Lord R, Hull MA, Subramanian V. Decreasing risk of first and subsequent surgeries in patients with Crohn’s disease in England from 1994 through 2013. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.12.022.

    Article  PubMed  Google Scholar 

  14. Diederen K, de Ridder L, van Rheenen P, et al. Complications and disease recurrence after primary ileocecal resection in pediatric Crohn’s disease: a multicenter cohort analysis. Inflamm Bowel Dis. 2017;23:272–82.

    PubMed  Google Scholar 

  15. Bobanga ID, Bai S, Swanson MA, et al. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn’s disease. Am J Surg. 2014;208:591–6.

    PubMed  Google Scholar 

  16. Onali S, Petruzziello C, Calabrese E, et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn’s disease after resection different from ileo-colonic. J Gastrointest Surg. 2009;13:246–52.

    PubMed  Google Scholar 

  17. Hammoudi N, Cazals-Hatem D, Auzolle C, et al. Association between microscopic lesions at ileal resection margin and recurrence after surgery in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.04.045.

    Article  PubMed  Google Scholar 

  18. Auzolle C, Nancey S, Tran-Minh ML, et al. Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn’s disease: results from a prospective cohort study. Aliment Pharmacol Ther. 2018;48:924–32.

    PubMed  Google Scholar 

  19. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.

    CAS  PubMed  Google Scholar 

  20. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Landsend E, Johnson E, Johannessen H-O, Carlsen E. Long-term outcome after intestinal resection for Crohn’s disease. Scand J Gastroenterol. 2006;41:1204–8.

    PubMed  Google Scholar 

  23. Abdelaal K, Jaffray B. Colonic disease site and perioperative complications predict need for later intestinal interventions following intestinal resection in pediatric Crohn’s disease. J Pediatr Surg. 2016;51:272–6.

    PubMed  Google Scholar 

  24. Onali S, Calabrese E, Petruzziello C, Lolli E, et al. Post-operative recurrence of Crohn’s disease: a prospective study at 5 years. Dig Liver Dis. 2016;48:489–94.

    PubMed  Google Scholar 

  25. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50.

    CAS  PubMed  Google Scholar 

  26. Walters TD, Steinhart AH, Bernstein CN, et al. Validating Crohn’s disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis. 2011;17:1547–56.

    CAS  PubMed  Google Scholar 

  27. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–30.

    PubMed  Google Scholar 

  28. Rivière P, Vermeire S, Irles-Depe M, et al. No change in determining Crohn’s disease recurrence or need for endoscopic or surgical intervention with modification of the Rutgeerts’ scoring system. Clin Gastroenterol Hepatol. 2019;17:1643–5.

    PubMed  Google Scholar 

  29. Blum E, Katz JA. Postoperative therapy for Crohn’s disease. Inflamm Bowel Dis. 2009;15:463–72.

    PubMed  Google Scholar 

  30. Pascua M, Su C, Lewis JD, Brensinger C, Lichtenstein GR. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn’s disease. Aliment Pharmacol Ther. 2008;28:545–56.

    CAS  PubMed  Google Scholar 

  31. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23:1213–21.

    PubMed  Google Scholar 

  32. Simillis C, Yamamoto T, Reese GE, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn’s disease. Am J Gastroenterol. 2008;103:196–205.

    PubMed  Google Scholar 

  33. McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M, Investigators of the CAST Trial. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52:919–27.

    PubMed  Google Scholar 

  34. Lazarev M, Huang C, Bitton A, Cho J, Duerr R, McGovern D, et al. Relationship between proximal Crohn’s disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterol. 2013;108:106–12.

    CAS  PubMed  Google Scholar 

  35. Holt DQ, Moore GT, Strauss BJ, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2017;45:1255–64.

    CAS  PubMed  Google Scholar 

  36. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385:1406–17.

    PubMed  Google Scholar 

  37. Regueiro M, Kip KE, Schraut W, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17(1):118–26.

    PubMed  Google Scholar 

  38. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96:663–74.

    CAS  PubMed  Google Scholar 

  39. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10:17–22.

    CAS  PubMed  Google Scholar 

  40. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–72.

    CAS  PubMed  Google Scholar 

  41. De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients—a POCER study analysis. Aliment Pharmacol Ther. 2015;42:867–79.

    PubMed  Google Scholar 

  42. Lopes S, Andrade P, Afonso J, et al. Correlation between calprotectin and modified Rutgeerts score. Inflamm Bowel Dis. 2016;22(9):2173–81.

    PubMed  Google Scholar 

  43. Hukkinen M, Pakarinen MP, Merras-Salmio L, et al. Fecal calprotectin in the prediction of postoperative recurrence of Crohn’s disease in children and adolescents. J Pediatr Surg. 2016;51:1467–72.

    PubMed  Google Scholar 

  44. Koilakou S, Sailer J, Peloschek P, et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn’s disease after ileocolic resection. Inflamm Bowel Dis. 2010;16:198–203.

    PubMed  Google Scholar 

  45. Amil-Dias J, Kolacek S, Turner D, et al. Surgical management of Crohn disease in children: guidelines from the paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2017;64:818–35.

    PubMed  Google Scholar 

  46. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.

    CAS  PubMed  Google Scholar 

  47. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–49.

    PubMed  Google Scholar 

  48. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.

    CAS  PubMed  Google Scholar 

  49. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009. https://doi.org/10.1002/14651858.

    Article  PubMed  Google Scholar 

  50. Burr NE, Hall B, Hamlin PJ, Selinger CP, Ford AC, O’Connor A. Systematic review and network meta-analysis medical therapies to prevent recurrence of post-operative Crohn’s disease. J Crohns Colitis. 2019;13:693–701.

    PubMed  Google Scholar 

  51. Herfarth HH, Katz JA, Hanauer SB, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013;19:1073–9.

    PubMed  PubMed Central  Google Scholar 

  52. Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.

    Article  PubMed  Google Scholar 

  53. Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:413–20.

    CAS  PubMed  Google Scholar 

  54. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723–9.

    CAS  PubMed  Google Scholar 

  55. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology. 2004;127:730–40.

    CAS  PubMed  Google Scholar 

  56. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–96.

    CAS  PubMed  Google Scholar 

  57. D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–9.

    PubMed  Google Scholar 

  58. Domènech E, Garcia V, Iborra M, et al. Incidence and management of recurrence in patients with Crohn’s disease who have undergone intestinal resection: the practicrohn study. Inflamm Bowel Dis. 2017;23:1840–6.

    PubMed  Google Scholar 

  59. Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, TOPPIC Study Group, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273–82.

    PubMed  PubMed Central  Google Scholar 

  60. Herfarth H, Tjaden C, Lukas M, Obermeier F, Dilger K, Mueller R, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn’s disease. Gut. 2006;55:1525–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12:1494–502.

    CAS  PubMed  Google Scholar 

  62. Aguas M, Bastida G, Cerrillo E, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol. 2012;18:4391–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J Crohn’s Colitis. 2012;6:924–31.

    Google Scholar 

  64. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804–7.

    PubMed  Google Scholar 

  65. Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L. Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis. 2015;47:191–6.

    CAS  PubMed  Google Scholar 

  66. Zhao Y, Ma T, Chen YF, et al. Biologics for the prevention of postoperative Crohn’s disease recurrence: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:637–49.

    PubMed  Google Scholar 

  67. Nguyen DL, Solaimani P, Nguyen ET, Jamal MM, Bechtold ML. Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:1152–9.

    CAS  PubMed  Google Scholar 

  68. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150:1568–78.

    CAS  PubMed  Google Scholar 

  69. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol. 2013;108:1731–42.

    CAS  PubMed  Google Scholar 

  70. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148:64–76.

    CAS  PubMed  Google Scholar 

  71. Preda CM, Fulger LE, Negreanu L, Manuc M, Sandra I, Diculescu MM. Adalimumab versus infliximab in treating post-operative recurrence of Crohn’s disease: a national cohort study. Rev Esp Enferm Dig. 2016;108:642–7.

    CAS  PubMed  Google Scholar 

  72. Assa A, Bronsky J, Kolho KL, et al. Anti-TNFα treatment after surgical resection for Crohn’s disease is effective despite previous pharmacodynamic failure. Inflamm Bowel Dis. 2017;23:791–7.

    PubMed  Google Scholar 

  73. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

    CAS  Google Scholar 

  74. Sakuraba A, Okamoto S, Matsuoka K, et al. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn’s disease. Digestion. 2015;91:233–8.

    CAS  PubMed  Google Scholar 

  75. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis. 2016;10:1259–66.

    PubMed  Google Scholar 

  76. Cohen-Mekelburg S, Gold S, Schneider Y, et al. Delays in initiating post-operative prophylactic biologic therapy are common among Crohn’s disease patients. Dig Dis Sci. 2019;64:196–203.

    PubMed  Google Scholar 

  77. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology. 1999;116:294–300.

    CAS  PubMed  Google Scholar 

  78. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF, German Budesonide Study Group. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 1999;11:277–82.

    CAS  PubMed  Google Scholar 

  79. Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for postoperative Crohn’s disease. Aliment Pharmacol Ther. 2010;31:802–9.

    CAS  PubMed  Google Scholar 

  80. Fedorak RN, Feagan BG, Hotte N, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:928–35.

    CAS  PubMed  Google Scholar 

  81. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25:67–72.

    CAS  PubMed  Google Scholar 

  82. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.

    PubMed  Google Scholar 

  83. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59:752–9.

    CAS  PubMed  Google Scholar 

  84. Baudry C, Pariente B, Lourenço N, et al. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn’s disease: a retrospective study. Dig Liver Dis. 2014;46:887–92.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Gastroenterology Unit, ‘Dana-Dwek’ Children’s Hospital, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

    Anat Yerushalmy-Feler

  2. Institute of Gastroenterology, Nutrition and Liver Disease, Schneider Children’s Medical Center of Israel, 14 Kaplan Street, 4920235, Petach-Tikva, Israel

    Amit Assa

  3. The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Anat Yerushalmy-Feler & Amit Assa

Authors
  1. Anat Yerushalmy-Feler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit Assa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amit Assa.

Ethics declarations

Funding

No funding was secured for this study.

Conflict of interest

AA: Consultation and lectures fees from AbbVie. Research grants, AbbVie and Janssen. AYF has no conflict of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yerushalmy-Feler, A., Assa, A. Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn’s Disease. Pediatr Drugs 21, 451–460 (2019). https://doi.org/10.1007/s40272-019-00361-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-019-00361-7

Search

Navigation